

Vaccine Trade and Generic Name Table

Vaccine	Trade name/	Antigen	Available via national Immunisation Programme	Notes
Please prescribe generic and brand to avoid confusion.				
DTap-IPV-Hep B/Hib	Infanrix-hexa® GSK	Diphtheria, tetanus, pertussis, polio, Hepatitis B and Haemophilus influenzae type b	Yes – for < 10 years old	Funding criteria: <ul style="list-style-type: none"> An additional 4 doses are funded for (re-) immunization for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; or other severely immunosuppressive regimens.
Tdap	Boostrix® GSK	Diphtheria, tetanus, pertussis	Yes – for > 7 years old to 18 years old	Funding criteria: <ul style="list-style-type: none"> An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post- solid organ transplant, renal dialysis and other severely immunosuppressive regimens <p>Note: Tdap is not registered for patients aged less than 10 years – refer to immunization handbook.</p>
DTap-IPV	Infanrix-IPV® Sanofi Pasteur	Diphtheria, tetanus, pertussis, polio	Yes – for < 10 years old	Funding criteria: <ul style="list-style-type: none"> An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplant, renal dialysis and other severely immunosuppressive regimens.
IPV	IPOL® Sanofi Pasteur	Inactivated polio vaccine	Yes	Funding criteria: <ul style="list-style-type: none"> For revaccination following immunosuppression.
23PPV	Pneumovax 23® MSD	23-valent polysaccharide pneumococcal	Yes, for high risk patients and for pre- and post-splenectomy under the age of 18 years and ≥ 2years	Funding criteria: <ul style="list-style-type: none"> Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or Up to two doses are funded for high risk children to the age of 18;
PCV-13	Prevenar 13® Pfizer	13-valent conjugate pneumococcal	Yes, for high risk programme (<5 years)	Funding criteria: <ul style="list-style-type: none"> Up to an additional four doses (as appropriate) are funded for (re-) immunisation of patients with HIV, for patients post haematopoietic stem cell transplantation HSCT, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

ACYW135	Menactra® Sanofi pasteur	Quadrivalent meningococcal ACYW - 135 polysaccharide (Neisseria meningitides)	Yes, for pre- and post-splenectomy or with functional asplenia	<p>Funding criteria:</p> <ul style="list-style-type: none"> • Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or • A maximum of two doses for bone marrow transplant patients; or • A maximum of two doses for patients following immunosuppression*. <p>*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.</p>
MenCCV	NeisVacC	Conjugate meningococcal C (Neisseria meningitides)	Yes, for pre- and post-splenectomy or with functional asplenia	<p>Recommended in asplenic/hyposplenic neonates</p> <p>Funding criteria:</p> <ul style="list-style-type: none"> • Up to 3 doses and a booster every 5 years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, or • One dose for close contacts of meningococcal cases; or • A maximum of two doses for bone marrow transplant patients; or • A maximum of two doses for patients following immunosuppression*. <p>Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly</p>
Hib	ActHib® Sanofi Pasteur	Monovalent Haemophilus influenzae type b	Yes	<p>Funding criteria:</p> <ul style="list-style-type: none"> • An additional dose (as appropriate) is funded for (re-) immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post-solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens.
Hep B	HBvaxPRO® MSD	Hepatitis B	Yes – 2 strengths available 5µg /10µg	<p>Funding criteria:</p> <ul style="list-style-type: none"> • For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or • For patients following immunosuppression; or • For transplant patients

VZV	Varilrix® GSK	Varicella zoster virus - Live vaccine	Yes – for high-risk groups and their contacts.	<p>Funding criteria:</p> <ul style="list-style-type: none"> • For non-immune patients: <ol style="list-style-type: none"> 1. With chronic liver disease who may in future be candidates for transplantation; or 2. With deteriorating renal function before transplantation; or 3. Prior to solid organ transplant; or 4. Prior to any elective immunosuppression*. • For patients at least 2 years after bone marrow transplantation, on advice of their specialist. • For patients at least 6 months after completion of chemotherapy, on advice of their specialist. • For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella. • For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella
HPV	Gardasil® MSD	Human papillomavirus	Yes	<p>Funding criteria:</p> <p>Maximum of three doses for patient meeting any of the following criteria:</p> <ul style="list-style-type: none"> • Females aged under 20 years old; or • Patients aged under 26 years old with confirmed HIV infection; or • For use in transplant (including stem cell) patients; or • An additional dose for patients under 26 years of age post chemotherapy.
MMR	M-M-R-II® MSD	Mumps, measles, rubella	Yes	<p>Funding criteria:</p> <p>A maximum of two doses for any patient meeting the following criteria:</p> <ul style="list-style-type: none"> • For revaccination following immunosuppression; or • For any individual susceptible to measles, mumps or rubella; or • A maximum of three doses for children who have had their first dose prior to 12 months.
Influenza	Brand varies	Influenza virus	<p>Yes for any cancer patient.</p> <p>Not funded for family members unless meet other MOH funding criteria</p> <p>www.influenza.org.nz</p>	<p>Individuals aged 9 years and older receive a single dose of vaccine.</p> <p>Children aged < 9 years who have not previously received influenza vaccine require two doses four weeks apart to produce satisfactory immune response.</p> <p>Regardless of age, previously unvaccinated immunosuppressed or immune-deficient individuals are recommended to receive two doses of influenza vaccine, four weeks apart.</p>